Why it matters
The list can be used as a structured baseline for monitoring category growth, specialties, manufacturers, and regulatory pathways rather than relying on marketing claims about 'medical AI'.
Decision implication
Ingest the authorized-device list into P4L's Intelligence Graph and compare authorization with real-world adoption, evidence, workflow, and postmarket monitoring.
Who or what is affected
- FDA
- device manufacturers
- health systems
- investors
- clinicians
Evidence and sources
E5 — official FDA source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- New authorizations
- specialty mix
- update cadence
- postmarket evidence.
Related proof records
- No linked public proof claim yet.